Source: St Louis Post Dispatch

Amplyx: San Diego biotech raises $90 million to treat infections in people with weak immune systems

SAN DIEGO - San Diego biotech company Amplyx Pharmaceuticals announced Tuesday that it has completed a $53 million extension to its Series C funding round, bringing the total for the round to $90 million. Sofinnova Venture Partners led the round,...

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Est. Annual Revenue
Est. Employees
Ciara Kennedy's photo - President & CEO of Amplyx

President & CEO

Ciara Kennedy

CEO Approval Rating


Amplyx is a biotechnology company that researches, develops and commercializes novel therapeutics for the treatment of fungal infections. Read more